NASDAQ:RARE

Ultragenyx Pharmaceutical Stock Insider Trading

Healthcare > Biotechnology

Buy RARE

*Your capital is at risk

$22.41

+0.630 (+2.89%)

At Close: Jun 03, 2026

Ultragenyx Pharmaceutical Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -13.12. In total, the insiders bought 1.31M and sold 169.14K RARE shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-13.12
● Buy	1.31M shares
● Sell	169.14K shares
65% Buy Activity Negligible or No Correlation
Buy Signal Low Confidence Apr 16, 2026 Analysis Breakdown: Weakened by a contradictory negative Insider Power Score. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 01, 2026 Sell	Common Stock S-Sale	Horn Howard Chief Financial Officer	C-Suite Officer	4 653 Value: $110.6K
May 18, 2026 Sell	Common Stock S-Sale	Suliman Shehnaaz Director	Director	5 740 Value: $144.2K
May 14, 2026 Buy	Stock Option (Right to Buy) A-Award	Dunsire Deborah Director	Director	14 058 Value: $362.7K
May 14, 2026 Buy	Common Stock A-Award	Fust Matthew K Director	Director	7 751 Value: $200.0K
May 14, 2026 Buy	Stock Option (Right to Buy) A-Award	Fust Matthew K Director	Director	14 058 Value: $362.7K
May 14, 2026 Buy	Common Stock A-Award	Suliman Shehnaaz Director	Director	7 751 Value: $200.0K
May 14, 2026 Buy	Stock Option (Right to Buy) A-Award	Suliman Shehnaaz Director	Director	14 058 Value: $362.7K
May 14, 2026 Buy	Common Stock A-Award	Ray Amrit Director	Director	7 751 Value: $200.0K
May 14, 2026 Buy	Stock Option (Right to Buy) A-Award	Ray Amrit Director	Director	14 058 Value: $362.7K
May 14, 2026 Buy	Common Stock A-Award	Sanders Corazon (corsee) D. Director	Director	7 751 Value: $200.0K
May 14, 2026 Buy	Stock Option (Right to Buy) A-Award	Sanders Corazon (corsee) D. Director	Director	14 058 Value: $362.7K
May 14, 2026 Buy	Common Stock A-Award	Narachi Michael Director	Director	7 751 Value: $200.0K
May 14, 2026 Buy	Stock Option (Right to Buy) A-Award	Narachi Michael Director	Director	14 058 Value: $362.7K
May 14, 2026 Buy	Common Stock A-Award	Welch Daniel G Director	Director	7 751 Value: $200.0K
May 14, 2026 Buy	Stock Option (Right to Buy) A-Award	Welch Daniel G Director	Director	14 058 Value: $362.7K
May 14, 2026 Buy	Common Stock A-Award	Dunsire Deborah Director	Director	7 751 Value: $200.0K
May 05, 2026 Sell	Common Stock S-Sale	Crombez Eric EVP And Chief Medical Officer	Officer	344 Value: $9K
May 01, 2026 Sell	Common Stock S-Sale	Horn Howard Chief Financial Officer	C-Suite Officer	4 683 Value: $116.6K
Apr 22, 2026 Buy	Stock Option (Right to Buy) A-Award	Huizenga Theodore Alan SVP, Chief Accounting Officer	Officer	7 348 Value: $180.8K
Apr 22, 2026 Buy	Common Stock A-Award	Huizenga Theodore Alan SVP, Chief Accounting Officer	Officer	20 241 Value: $498.1K
Apr 16, 2026 Buy	Stock Option (Right to Buy) A-Award	Horn Howard Chief Financial Officer	C-Suite Officer	59 952 Value: $1.47M
Apr 16, 2026 Buy	Stock Option (Right to Buy) A-Award	Crombez Eric EVP And Chief Medical Officer	Officer	59 952 Value: $1.47M
Apr 16, 2026 Buy	Stock Option (Right to Buy) A-Award	Harris Erik EVP & Chief Commercial Officer	Officer	49 960 Value: $1.23M
Apr 16, 2026 Buy	Stock Option (Right to Buy) A-Award	Parschauer Karah Herdman EVP And Chief Legal Officer	Officer	49 960 Value: $1.23M
Apr 16, 2026 Buy	Stock Option (Right to Buy) A-Award	Pinion John Richard See Remarks	Officer	79 936 Value: $1.96M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ULTRAGENYX PHARMACEUTICAL INC.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia...

Read Full Profile Here